(Total Views: 671)
Posted On: 08/12/2020 1:05:13 PM
Post# of 153886
Re: chessmaster #48800
Re: Article JUST OUT
There is something very interesting in the article:
"This drug isn’t a one trick pony and the NEWS2 endpoint was developed by the Royal College of Physicians in England. So the likelihood of approval in England is quite high because this is the first trial to have statistically significant efficacy data and uses their own scoring system. It is important to note that no other trial in mild to moderate COVID-19 patients anywhere in the world has reported any efficacy."
So if this gives us a leg up with approval in GB, then it certainly IS needle moving.
There is something very interesting in the article:
"This drug isn’t a one trick pony and the NEWS2 endpoint was developed by the Royal College of Physicians in England. So the likelihood of approval in England is quite high because this is the first trial to have statistically significant efficacy data and uses their own scoring system. It is important to note that no other trial in mild to moderate COVID-19 patients anywhere in the world has reported any efficacy."
So if this gives us a leg up with approval in GB, then it certainly IS needle moving.
(12)
(0)
